Keyphrases
Programmed Death-ligand 1 (PD-L1)
100%
Inflammatory Breast Cancer
100%
Inflammatory Breast Carcinoma
66%
Overall Survival
50%
Programmed Death-ligand 1 Expression
33%
Breast Cancer
16%
Multivariate Analysis
16%
Clinical Outcomes
16%
5-year Survival
16%
Melanoma
16%
Patient Selection
16%
Non-small Cell Lung Cancer (NSCLC)
16%
Univariate Analysis
16%
U.S. Food
16%
Antibody Clones
16%
Overall Survival Rate
16%
Estrogen Receptor-negative
16%
Detection System
16%
Anti-programmed Death 1
16%
Anti-programmed death-1 Monoclonal Antibody
16%
Tissue Microarray
16%
Programmed death-1 Inhibitor
16%
Triple-negative Status
16%
Medicine and Dentistry
Programmed Death 1 Ligand 1
100%
Inflammatory Breast Cancer
100%
Overall Survival
36%
Breast Cancer
9%
Survival Rate
9%
Estrogen Receptor
9%
Univariate Analysis
9%
Non Small Cell Lung Cancer
9%
Tissue Microarray
9%
Melanoma
9%
Multivariate Analysis
9%
Pharmacology, Toxicology and Pharmaceutical Science
Programmed Death 1 Ligand 1
100%
Inflammatory Breast Cancer
100%
Overall Survival
36%
Survival Rate
9%
Estrogen Receptor
9%
Breast Cancer
9%
Melanoma
9%
Non Small Cell Lung Cancer
9%